This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
From 18 Years to 75 Years.
- Participants should have successfully completed treatment in the M16-046 study,
without meeting any permanent discontinuation criteria.
- Participant is judged to be in general good health (other than AD) as determined by
the Principal Investigator and remains eligible as per the criteria for the study
M16-046 to continue treatment in the long term extension study.
- Requirement of prohibited medications during the study treatment or would interfere
with appropriate assessment of atopic dermatitis lesions.
- Female participant who is pregnant, breastfeeding, or considering pregnancy during the